U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416552) titled 'A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)' on Feb. 11.
Brief Summary: This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer
Intervention:
DRUG: SPLIT Abs
Participants will receive SPLIT Abs as part of the pretargeting regimen per the sch...